Abstract
Chronic Hand Eczema – Unmet Needs and New Therapeutic Approach with Topical JAK Inhibitor Delgocitinib
Department of Dermatology, Centre of Postgraduate Medical Education, Warsaw, Poland
Dermatology Clinic National Institute of Medicine of the Ministry of Interior and Administration, Warsaw, Poland
Department of Dermatology, Military Institute of Medicine – National Research Institute, Warsaw, Poland
Department of Dermatology, Faculty of Medicine, Collegium Medicum, Jan Kochanowski University, Kielce, Poland
Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Poland
Department of Dermatology, Venereology and Allergology, University Clinical Center, Gdansk, Poland
Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland
Department of Dermato-Venereology, 4th Military Hospital, Wroclaw, Poland
Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Poland
Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Medical University of Lodz, Poland
Department of Dermatology, Faculty of Medicine, University of Rzeszow, Poland
Dermatol Rev/Przegl Dermatol 2026, 113, 204–218
Chronic hand eczema is a common, recurrent and clinically heterogeneous inflammatory dermatosis with a significant health, professional and social impact. The condition may have a complex etiology, involving atopic, allergic and/or irritant factors, and its clinical presentation often fluctuates over time, complicating classification, etiological diagnostics and optimal treatment selection. The cornerstone of management remains the identification and reduction of exposure to triggering factors, restoration of the skin barrier, and anti-inflammatory treatment, mainly with topical corticosteroids. In some patients, particularly those with moderate to severe, recurrent or refractory chronic hand eczema, the standard treatment options do not provide sustained disease control or are associated with significant limitations regarding safety, tolerability and availability of treatment. The functional consequences of chronic hand eczema are also of particular significance, including pain, itching, skin fissures, reduced manual dexterity, sickness absenteeism, presenteeism and reduced quality of life. The approval of delgocitinib cream, a topical Janus kinase inhibitor, has transformed the therapeutic landscape for chronic hand eczema, introducing a topical targeted therapy for adults with moderate to severe disease for whom topical corticosteroids are inadequate or inappropriate. Data from the DELTA trial programme demonstrate the efficacy of delgocitinib in reducing lesion severity, pruritus and pain, quality of life improvement, and favourable safety profile. However, significant challenges remain regarding treatment accessibility, etiological diagnostics, prevention of flare-ups and the optimal positioning of new medicinal products within the chronic hand eczema treatment algorithm.
Keywords
chronic hand eczema, delgocitinib, topical JAK inhibitor, topical corticosteroids, quality of life, contact eczema, patch tests, unmet medical needs
Coverage in
Integrated with

